A director at Absci purchased 37,453 shares, showing confidence despite the company's Q1 2026 revenue missing estimates by 90%. Absci reported a smaller-than-expected loss and progress in its ABS-201 clinical trial with positive safety data. The insider buy highlights belief in Absci's future as it advances its drug pipeline, including ABS-202. CEO Sean McClain expects 2026 to be a data-rich year, potentially boosting the biotech's outlook.
Birkenstock's stock fell over 13% after reporting Q2 earnings of $0.59 per share, missing the expected $0.70. The company faced profitability pressure due to a gross margin decline from 57.7% to 53.9%, impacted by currency issues, higher US tariffs, ...
Siemens AG reported mixed Q2 2026 results with earnings per share and revenue slightly below analyst expectations, impacted by a challenging geopolitical environment. Despite this, the company experienced an 18% increase in orders and a record €124 b...
Fiserv has agreed with Bridgeport Partners to create a joint venture combining Fiserv’s ATM Managed Services, Cash & Logistics, and MoneyPass businesses. This partnership aims to leverage Fiserv’s industry expertise and Bridgeport’s operational focus...
Wrap Technologies reported a 45% revenue increase to $1.1 million in Q1 2026, driven by strong domestic and international demand for its non-lethal BolaWrap 150 product. The company secured a significant purchase order from the U.S. Department of Hom...
Mdxhealth reported a 13% revenue increase to $27.4 million in Q1 2026 but decided to discontinue its Resolve UTI test and Plano lab due to reimbursement challenges. The company is refocusing on its core prostate cancer diagnostics and integrating AI ...
